These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 9085134

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment.
    Knapp FF, Beets AL, Guhlke S, Zamora PO, Bender H, Palmedo H, Biersack HJ.
    Anticancer Res; 1997; 17(3B):1783-95. PubMed ID: 9179235
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
    Kramer TH, Shook JE, Kazmierski W, Ayres EA, Wire WS, Hruby VJ, Burks TF.
    J Pharmacol Exp Ther; 1989 May; 249(2):544-51. PubMed ID: 2566679
    [Abstract] [Full Text] [Related]

  • 7. Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly-radiolabeled somatostatin analogue.
    Zamora PO, Gulhke S, Bender H, Diekmann D, Rhodes BA, Biersack HJ, Knapp FF.
    Int J Cancer; 1996 Jan 17; 65(2):214-20. PubMed ID: 8567120
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
    Nagy A, Schally AV, Halmos G, Armatis P, Cai RZ, Csernus V, Kovács M, Koppán M, Szepesházi K, Kahán Z.
    Proc Natl Acad Sci U S A; 1998 Feb 17; 95(4):1794-9. PubMed ID: 9465096
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of (111)In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors.
    Bernhardt P, Ahlman H, Nilsson O, Benjegård SA, Forssell-Aronsson E.
    Cancer Biother Radiopharm; 2003 Apr 17; 18(2):249-52. PubMed ID: 12804051
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. De novo design, synthesis, and pharmacology of alpha-melanocyte stimulating hormone analogues derived from somatostatin by a hybrid approach.
    Han G, Haskell-Luevano C, Kendall L, Bonner G, Hadley ME, Cone RD, Hruby VJ.
    J Med Chem; 2004 Mar 11; 47(6):1514-26. PubMed ID: 14998337
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K, Schally AV, Cai RZ, Radulovic S, Milovanovic S, Szoke B.
    Cancer Res; 1991 Nov 01; 51(21):5980-6. PubMed ID: 1682039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.